Altamira Therapeutics Ltd. Proceeds From Issue Of Ordinary Shares
Altamira Therapeutics Ltd. (CYTOF) reported Proceeds From Issue Of Ordinary Shares of $12.10 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-05-16.
Discontinued › Cash Flow › Financing Activities
ifrs-full:ProceedsFromIssueOfOrdinaryShares · last filed 2024-04-22
CHF
| Period end | Proceeds From Issue Of Ordinary Shares 0 month | Proceeds From Issue Of Ordinary Shares 1 month | Proceeds From Issue Of Ordinary Shares 12 month |
|---|---|---|---|
| 2019-12-31 | 978.41K CHF 20-F · filed 2020-04-16 | ||
| 2019-08-09 | 1.30M CHF 6-K · filed 2019-08-15 | ||
| 2018-11-30 | 25.00M CHF 20-F · filed 2020-04-16 | ||
| 2018-05-02 | 89.88K CHF 20-F · filed 2020-04-16 | ||
| 2018-01-31 | 341.23K CHF 6-K · filed 2019-08-15 |
USD
| Period end | Proceeds From Issue Of Ordinary Shares | Proceeds From Issue Of Ordinary Shares 1 month | Proceeds From Issue Of Ordinary Shares 12 month |
|---|---|---|---|
| 2022-12-31 | $12.10M 20-F · filed 2023-05-16 | ||
| 2021-12-31 | $5.40M 20-F · filed 2022-04-12 | ||
| 2020-12-31 | $3.20M 20-F · filed 2021-03-31 | ||
| 2018-11-30 | $13.10 20-F/A · filed 2024-04-22 | $25.00M 6-K · filed 2023-09-12 |